Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Hu, Xingsheng
116  Ergebnisse:
Personensuche X
?
1

Safety, tolerability, and pharmacokinetics of simotinib, a ..:

Hu, Xing-sheng ; Han, Xiao-hong ; Yang, Sheng...
info:eu-repo/semantics/altIdentifier/doi/10.2147/CMAR.S189626.  , 2019
Link: https://www.dovepress.co..
 
?
2

Known actionable driver oncogene mutations were excluded fr..:

Xingsheng Hu ; Chunhong Hu ; Ping Zhong
https://figshare.com/articles/dataset/Known_actionable_driver_oncogene_mutations_were_excluded_from_neoadjuvant_chemoimmunotherapy_of_non-small_cell_lung_cancer_/25139045.  , 2024
Link: https://doi.org/10.6084/..
 
?
3

Actionable driver oncogene mutations were excluded from neo..:

Xingsheng Hu ; Ping Zhong ; Chaoyuan Liu...
https://figshare.com/articles/dataset/Actionable_driver_oncogene_mutations_were_excluded_from_neoadjuvant_chemoimmunotherapy_of_non-small_cell_lung_cancer/25375123.  , 2024
Link: https://doi.org/10.6084/..
 
?
4

Known actionable driver oncogene mutations were excluded fr..:

Xingsheng Hu
doi:10.6084/m9.figshare.25138370.v1.  , 2024
Link: https://doi.org/10.6084/..
 
?
5

Known actionable driver oncogene mutations were excluded fr..:

Xingsheng Hu ; Chunhong Hu ; Ping Zhong
doi:10.6084/m9.figshare.25139045.v1.  , 2024
Link: https://doi.org/10.6084/..
 
?
6

Known actionable driver oncogene mutations were excluded fr..:

Xingsheng Hu
https://figshare.com/articles/dataset/Known_actionable_driver_oncogene_mutations_were_excluded_from_neoadjuvant_chemoimmunotherapy_of_non-small_cell_lung_cancer_/25138370.  , 2024
Link: https://doi.org/10.6084/..
 
?
7

Actionable driver oncogene mutations were excluded from neo..:

Xingsheng Hu ; Ping Zhong ; Chaoyuan Liu...
doi:10.6084/m9.figshare.25275916.v1.  , 2024
Link: https://doi.org/10.6084/..
 
?
8

Actionable driver oncogene mutations were excluded from neo..:

Xingsheng Hu ; Ping Zhong ; Chaoyuan Liu...
https://figshare.com/articles/dataset/Actionable_driver_oncogene_mutations_were_excluded_from_neoadjuvant_chemoimmunotherapy_of_non-small_cell_lung_cancer_/25275916.  , 2024
Link: https://doi.org/10.6084/..
 
?
9

Table_1_Efficacy and safety of immunotherapy combined with ..:

Dongna Chen ; Lin Li ; Mingzhao Wang...
doi:10.3389/fimmu.2023.1086479.s002.  , 2023
Link: https://doi.org/10.3389/..
 
?
10

Table_5_Tumor regression rate, PD-L1 expression, pembrolizu..:

Xingsheng Hu ; Chunhong Hu ; Xianling Liu...
doi:10.3389/fonc.2022.1057646.s005.  , 2023
Link: https://doi.org/10.3389/..
 
?
11

Efficacy and safety of osimertinib plus anlotinib in advanc..:

Mingzhao Wang ; Jun Zhao ; Tong Chen...
https://doi.org/10.1111/1759-7714.14819.  , 2023
Link: https://doi.org/10.1111/..
 
?
12

Table_3_Tumor regression rate, PD-L1 expression, pembrolizu..:

Xingsheng Hu ; Chunhong Hu ; Xianling Liu...
doi:10.3389/fonc.2022.1057646.s003.  , 2023
Link: https://doi.org/10.3389/..
 
?
13

Efficacy and safety of immune checkpoint inhibitor rechalle..:

Yu Feng ; Yunxia Tao ; Haizhu Chen...
https://doi.org/10.1111/1759-7714.15063.  , 2023
Link: https://doi.org/10.1111/..
 
?
14

Efficacy and safety of immunotherapy combined with single-a..:

Dongna Chen ; Lin Li ; Mingzhao Wang...
https://www.frontiersin.org/articles/10.3389/fimmu.2023.1086479/full.  , 2023
Link: https://doi.org/10.3389/..
 
?
15

Table_1_Tumor regression rate, PD-L1 expression, pembrolizu..:

Xingsheng Hu ; Chunhong Hu ; Xianling Liu...
doi:10.3389/fonc.2022.1057646.s001.  , 2023
Link: https://doi.org/10.3389/..
 
1-15